{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Wet+Macular+Degeneration&page=3",
    "query": {
      "condition": "Age-related Wet Macular Degeneration",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 172,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Wet+Macular+Degeneration&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Wet+Macular+Degeneration&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T20:17:25.665Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07484074",
      "title": "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular (Wet) Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "OLN324",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ollin Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2025-02-12",
      "completion_date": "2025-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07484074"
    },
    {
      "nct_id": "NCT00538538",
      "title": "Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinal Hemorrhage",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "vitrectomy with subretinal lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-09",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2016-08-08",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538538"
    },
    {
      "nct_id": "NCT01255774",
      "title": "Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye & Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "51 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255774"
    },
    {
      "nct_id": "NCT01926977",
      "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.5mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arshad Khanani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926977"
    },
    {
      "nct_id": "NCT04200248",
      "title": "A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RBM-007 Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ribomic USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2019-12-02",
      "completion_date": "2021-12-22",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200248"
    },
    {
      "nct_id": "NCT02022540",
      "title": "Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "PAN-90806 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PanOptica, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 22,
      "location_summary": "Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02022540"
    },
    {
      "nct_id": "NCT00094120",
      "title": "MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With \"Wet\" Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MSI-1256F (Squalamine Lactate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genaera Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-10",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2008-01-09",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 1,
      "location_summary": "Plymouth Meeting, Pennsylvania",
      "locations": [
        {
          "city": "Plymouth Meeting",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094120"
    },
    {
      "nct_id": "NCT00259753",
      "title": "Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Bevasiranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-08-05",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00259753"
    },
    {
      "nct_id": "NCT06550011",
      "title": "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) AMD"
      ],
      "interventions": [
        {
          "name": "ABI-110 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "ABI-110 Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "ABI-110 High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avirmax Biopharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-07",
      "completion_date": "2031-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06550011"
    },
    {
      "nct_id": "NCT01674569",
      "title": "Pilot Study of X-82 in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Exudative Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "X-82 oral",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab (Lucentis)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyrogenex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-10",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-10T20:17:25.665Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "New London",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674569"
    }
  ]
}